Literature DB >> 19504558

Gene single nucleotide polymorphism accumulation improves survival in advanced head and neck cancer patients treated with weekly paclitaxel.

Juan J Grau1, Miguel Caballero, Marc Campayo, Sonia Jansa, Mauricio Vargas, Llucia Alós, Mariano Monzo.   

Abstract

OBJECTIVES/HYPOTHESIS: Single nucleotide polymorphisms (SNPs) of certain genes involved in drug metabolism correlate with survival.
METHODS: We evaluated the presence of SNPs in six genes (CYP2C8, GSTT1, GSTP1, MDR1-57, MDR1-62, and ERCC1) and the response rate (RR), time to progression (TTP), and overall survival (OS) of advanced head and neck cancer patients treated with weekly paclitaxel.
RESULTS: SNPs in CYP2C8, MDR1-57, and MDR1-62 genes were more frequent than wild-type genes in our patients. RR was 45% (21/47), and median TTP in responders was 5.1 months. OS for all patients was 5.6 months. Response was higher in SNPs of MDR1-62, MDR1-57, or in two or more accumulated genes than in those with wild-type genes. OS was significantly longer in patients with two or more accumulated SNPs (P = .039).
CONCLUSIONS: Response rate and OS were significantly higher in patients with two or more accumulated SNPs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19504558     DOI: 10.1002/lary.20254

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  7 in total

1.  PharmGKB summary: very important pharmacogene information for GSTT1.

Authors:  Caroline F Thorn; Yuan Ji; Richard M Weinshilboum; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2012-08       Impact factor: 2.089

Review 2.  Polymorphisms in DNA damage response genes and head and neck cancer risk.

Authors:  Rafael E Flores-Obando; Susanne M Gollin; Camille C Ragin
Journal:  Biomarkers       Date:  2010-08       Impact factor: 2.658

3.  Single nucleotide polymorphisms in nucleotide excision repair genes, cancer treatment, and head and neck cancer survival.

Authors:  Annah B Wyss; Mark C Weissler; Christy L Avery; Amy H Herring; Jeannette T Bensen; Jill S Barnholtz-Sloan; William K Funkhouser; Andrew F Olshan
Journal:  Cancer Causes Control       Date:  2014-02-02       Impact factor: 2.506

4.  Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.

Authors:  Stefanie D Krens; Howard L McLeod; Daniel L Hertz
Journal:  Pharmacogenomics       Date:  2013-04       Impact factor: 2.533

5.  Prognostic Value of Two Polymorphisms, rs1045642 and rs1128503, in ABCB1 Following Taxane-based Chemotherapy: A Meta-Analysis.

Authors:  Quanyao Chen; Wanlong Lin; Jianhui Yang; Min Lin; Xiuxian Lin; Yiyin Weng; Yao Chen
Journal:  Asian Pac J Cancer Prev       Date:  2021-01-01

6.  ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer.

Authors:  Alec Vaezi; Chelsea H Feldman; Laura J Niedernhofer
Journal:  Pharmgenomics Pers Med       Date:  2011-07-20

7.  Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel.

Authors:  Tulay Kus; Gokmen Aktas; Mehmet Emin Kalender; Abdullah Tuncay Demiryurek; Mustafa Ulasli; Serdar Oztuzcu; Alper Sevinc; Seval Kul; Celaletdin Camci
Journal:  Onco Targets Ther       Date:  2016-08-12       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.